Welcome to LookChem.com Sign In|Join Free

CAS

  • or

132740-58-0

Post Buying Request

132740-58-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

132740-58-0 Usage

Chemical class

Arylcyclohexylamine

Structural relation

Dissociative anesthetics (ketamine, phencyclidine)

Core structure

Phenethylamine with an attached piperidine ring

Potential effects

Psychoactive

Pharmacological action

Selective serotonin and dopamine reuptake inhibitor (theoretical)

Research status

Limited information available

Safety and toxicity

Not well understood

Human consumption

Not approved

Recreational use

Gained attention in recreational drug communities

Legal status

Varies by country/region

Check Digit Verification of cas no

The CAS Registry Mumber 132740-58-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,2,7,4 and 0 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 132740-58:
(8*1)+(7*3)+(6*2)+(5*7)+(4*4)+(3*0)+(2*5)+(1*8)=110
110 % 10 = 0
So 132740-58-0 is a valid CAS Registry Number.

132740-58-0Downstream Products

132740-58-0Relevant articles and documents

Structure-activity relationship study of tryptophan-based butyrylcholinesterase inhibitors

Brazzolotto, Xavier,Gobec, Stanislav,Gro?elj, Uro?,Knez, Damijan,Malikowska-Racia, Natalia,Meden, An?e,Nachon, Florian,Sa?at, Kinga,Svete, Jurij

, (2020)

A series of tryptophan-based selective nanomolar butyrylcholinesterase (BChE) inhibitors was designed and synthesized. Compounds were optimized in terms of potency, selectivity, and synthetic accessibility. The crystal structure of the inhibitor 18 in complex with BChE revealed the molecular basis for its low nanomolar inhibition (IC50 = 2.8 nM). The favourable in vitro results enabled a first-in-animal in vivo efficacy and safety trial, which demonstrated a positive impact on fear-motivated and spatial long-term memory retrieval without any concomitant adverse motor effects. Altogether, this research culminated in a handful of new lead compounds with promising potential for symptomatic treatment of patients with Alzheimer's disease.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 132740-58-0